A fresh set of brokerage reports has highlighted several stocks likely to remain in focus on April 22, 2026, with mixed sentiment across sectors such as IT, FMCG, pharma, and wealth management.
While firms like 360 One and Nestlé India saw strong optimism from analysts, concerns around HCL Technologies and Persistent Systems continue to weigh on sentiment.
Here’s a detailed look at the key stocks to watch today based on brokerage calls:
Tata Elxsi: Weak Q4 Performance Keeps Pressure On
Brokerage firm Morgan Stanley has maintained an ‘Underweight’ rating on Tata Elxsi, cutting the target price to ₹4,200 from ₹5,350.
The company reported a weak Q4, with revenue growth missing estimates due to softness in the healthcare segment. Although margins came in better than consensus, EBIT fell short of expectations.
Management has indicated recovery hopes by FY27, but growth projections have been lowered, signaling limited near-term upside.
Eris Lifesciences: Regulatory Observations in Focus
Macquarie has retained an ‘Outperform’ rating on Eris Lifesciences with a target price of ₹1,680.
The company’s manufacturing units were inspected by European regulators, resulting in procedural observations related to GMP compliance.
While the issues are not critical, achieving EU GMP certification remains crucial for the company’s export ambitions and CDMO strategy.
360 One: Strong Performance Drives Bullish Outlook
Brokerages remain upbeat on 360 One Wealth:
Citi has reiterated a ‘Buy’ rating with a target price of ₹1,525, highlighting strong profit growth and resilient performance despite a challenging market environment.
Jefferies has also maintained a ‘Buy’ rating, expecting sustained growth driven by strong inflows, transaction revenues, and synergies from acquisitions.
The company’s diversified multi-asset model continues to support stable growth momentum.
HCL Technologies: Weak Guidance Weighs on Sentiment
Multiple brokerages have turned cautious on HCL Technologies following a disappointing Q4 performance:
Citi, HSBC, JPMorgan, and CLSA have all flagged weak revenue growth, soft deal wins, and cautious FY27 guidance.
Key concerns include reduced discretionary spending in telecom, cancellation of SAP projects, and limited visibility on demand recovery.
Although some brokerages like Nomura maintain a ‘Buy’ stance, overall sentiment remains weak in the near term.
Persistent Systems: Mixed Signals Keep Analysts Divided
Persistent Systems delivered a mixed Q4, leading to divergent brokerage views:
CLSA and JPMorgan remain constructive, citing strong deal momentum and revenue visibility.
However, Citi has maintained a ‘Sell’ rating, pointing to high valuations and margin pressures.
The company continues to face headwinds from AI-led deflation and rising software costs, even as growth remains strong.
Nestlé India: Strong Growth Impresses Analysts
Nestlé India posted a strong quarter, attracting positive commentary from brokerages:
HSBC highlighted robust revenue growth and margin expansion despite higher advertising spends.
Nomura has maintained a ‘Buy’ rating, calling it a “blowout quarter” driven by strong volume growth and pricing mix.
However, some analysts remain cautious on valuations, given the stock’s premium multiples.
Cyient DLM: Growth Recovery Expected
JPMorgan remains optimistic on Cyient DLM with an ‘Overweight’ rating, expecting a sharp recovery in FY27 driven by easing headwinds and improved execution.
Macquarie, however, has taken a more cautious stance, citing delays in converting a strong order book into revenue.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.